Literature DB >> 21367993

Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.

Asma Lat1, Sarah A Clock, Fann Wu, Susan Whittier, Phyllis Della-Latta, Kathy Fauntleroy, Stephen G Jenkins, Lisa Saiman, Christine J Kubin.   

Abstract

We report MIC agreement and error rates between broth microdilution (BMD), Vitek 2, and Etest against 48 clinical KPC-producing Klebsiella pneumoniae isolates for polymyxin B, tigecycline, cefepime, and meropenem. Both commercial testing methods were useful for tigecycline testing; Etest provided a conservative estimate of polymyxin B susceptibility. We suggest that laboratories consider the supplemental use of reference BMD or Etest for cefepime and meropenem for susceptibility testing of KPC-producing K. pneumoniae, as Vitek 2 did not provide reliable results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367993      PMCID: PMC3122677          DOI: 10.1128/JCM.02534-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

3.  Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods.

Authors:  Catharine C Bulik; Kathy A Fauntleroy; Stephen G Jenkins; Mayssa Abuali; Vincent J LaBombardi; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2010-05-19       Impact factor: 5.948

Review 4.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.

Authors:  Simona Bratu; Mohamad Mooty; Satyen Nichani; David Landman; Carl Gullans; Barbara Pettinato; Usha Karumudi; Pooja Tolaney; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

7.  Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Mariana Castanheira; Hélio S Sader; Lalitagauri M Deshpande; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Authors:  Chris M Pillar; Deborah C Draghi; Michael J Dowzicky; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

9.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

10.  Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.

Authors:  Andrea Endimiani; Andrea M Hujer; Federico Perez; Christopher R Bethel; Kristine M Hujer; Jennifer Kroeger; Margret Oethinger; David L Paterson; Mark D Adams; Michael R Jacobs; Daniel J Diekema; Gerri S Hall; Stephen G Jenkins; Louis B Rice; Fred C Tenover; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2009-01-20       Impact factor: 5.790

View more
  24 in total

1.  Method for phenotypic detection of extended-spectrum beta-lactamases in enterobacter species in the routine clinical setting.

Authors:  James Cohen Stuart; Bram Diederen; Nashwan Al Naiemi; Ad Fluit; Niek Arents; Steven Thijsen; Bart Vlaminckx; Johan W Mouton; Maurine Leverstein-van Hall
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

2.  Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens.

Authors:  Olympia Zarkotou; Spyros Pournaras; George Altouvas; Vassiliki Pitiriga; Maria Tziraki; Vassiliki Mamali; Katerina Themeli-Digalaki; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2012-08-29       Impact factor: 5.948

3.  mgrB Mutations Mediating Polymyxin B Resistance in Klebsiella pneumoniae Isolates from Rectal Surveillance Swabs in Brazil.

Authors:  Caio Augusto Martins Aires; Polyana Silva Pereira; Marise Dutra Asensi; Ana Paula D'Alincourt Carvalho-Assef
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?

Authors:  Shawn Vasoo
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

5.  Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center.

Authors:  Dror Marchaim; Teena Chopra; Federico Perez; Kayoko Hayakawa; Paul R Lephart; Suchitha Bheemreddy; Christopher Blunden; Andrea M Hujer; Susan Rudin; Maryann Shango; Michelle Campbell; Jastin Varkey; Jessica Slim; Farah Ahmad; Diixa Patel; Ting-Yi Chen; Jason M Pogue; Hossein Salimnia; Sorabh Dhar; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09       Impact factor: 3.254

6.  Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.

Authors:  April M Bobenchik; Eszter Deak; Janet A Hindler; Carmen L Charlton; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

7.  First report of chronic pulmonary infection by KPC-3-producing and colistin-resistant Klebsiella pneumoniae sequence type 258 (ST258) in an adult patient with cystic fibrosis.

Authors:  Emanuele Delfino; Daniele Roberto Giacobbe; Valerio Del Bono; Erika Coppo; Anna Marchese; Graziana Manno; Patrizia Morelli; Laura Minicucci; Claudio Viscoli
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

8.  Evaluation of three different methods for susceptibility testing of gentamicin in carbapenem resistant Enterobacterales.

Authors:  Yeliz Tanriverdi Cayci; Kubra Hacieminoglu Ulker; Asuman Birinci
Journal:  Infez Med       Date:  2021-12-10

9.  Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.

Authors:  Maria Helena Rigatto; Fabiane J Vieira; Laura C Antochevis; Tainá F Behle; Natane T Lopes; Alexandre P Zavascki
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

10.  Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.

Authors:  Piergiorgio Cojutti; Assunta Sartor; Elda Righi; Claudio Scarparo; Matteo Bassetti; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.